The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Board Of Directors

 

Anna Ljung
M.Sc,
Chairman of the Board
since 2024
Mattias Klintemar
MBA,
Board Member
since 2021
Marianne Kock
MSc, MBA,
Board member
since 2021
Robert Molander
MBA,
Board Member
since 2024
Professional experience Professional experience Professional experience Professional experience
  • Anna Ljung holdes 0 shares and 0 warrants

  • Independent in relation to the company, to its senior executives and major shareholders

  • Anna Ljung has more than 20 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera

  • Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant.

  • Currently Anna is serving as CEO of Moberg Pharma and as Board member of Saniona AB and ADDvise Group AB.

  • Mattias Klintemar holds 34.285 shares

  • Dependent in relation to the company, independent in relation to its senior executives and major shareholders

  • Currently serves as Director of Investments at Östersjöstiftelsen

  • Has among others worked at ABG Sundal Collier and served as CEO at Morphic Technologies, CFO at Hexaformer, Chairman of the board at Dilafor and board member of Moberg Pharma, Axelar, Phoniro and DBT.

  • Board member at Oatly, Palette Life Sciences and Velove.
  • Currently serves as General Manager at Ferring Pharmaceuticals’ IPC Development Unit in Copenhagen.

  • Board member of Ferring Pharmaceutical (DK), Syntese (DK), Izvarino Pharma (Rus), NanoPharm (Rus) and Asarina (SE)

  • Previously, board member of Fertin Pharma (DK), Bionor Pharma (NO), Egalet (DK), Forward Pharma (DK) and Gastrotech Pharma (DK)
  • Robert Molander holds 0 shares and 0 warrants

  • Robert has more than 25 years of expertise in life science commercialization as Senior executive and advisor primarily based in the United States.

  • Robert has successfully led companies such as Novartis, Pfizer, Shionogi, and Trialbee through product launches, business development and scaling commercial operations. Robert has previously been Chief Commercial Officer at Infant Bacterial Therapeutics AB and Trialbee AB and a board member of Infant Bacterial Therapeutics AB

  • Currently Robert serves as Board member of Xspray Pharma AB, CEO of Stratfox Healthcare Group LLC.

Educational background Educational background Educational background Educational background 
  • M.Sc. Econ.
  • Bachelor of Business Administration (BBA), Accounting and Finance from Karlstad Universitett
  • Master’s degree in Pharmacy from Danish University of Pharmacy

  • Executive Master’s degree in Business Administration from Scandinavian International Management Institute
  • MBA in Marketing and Finance